We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
This study assessed whether or not SGLT2i prescription, compared with an active comparator, is associated with COVID-19. Results showed that among users of SGLT2is versus users of DPP4is, the incidence rate of COVID-19 was 19.7/1000 person-years and 24.7/1000 person-years, respectively.
The authors conclude that there was no increased risk of COVID-19 in the primary care setting among individuals prescribed SGLT2is compared with DPP4is. They state that these agents can be used safely to treat type 2 diabetes patients during the COVID-19 pandemic.
This abstract is available on the publisher's site.
Sodium/glucose co-transporter-2 inhibitors (SGLT2i) are widely prescribed in people with type 2 diabetes. We aimed to investigate whether SGLT2i prescription is associated with COVID-19, when compared with an active comparator. We performed a propensity score-matched cohort study with active comparators and a negative control outcome in a large UK-based primary care dataset. Participants prescribed SGLT2i (n = 9948) and a comparator group prescribed dipeptyl-peptidase 4 inhibitors (DPP4i; n = 14 917) were followed up from 30th January to 27th July 2020. The primary outcome was confirmed or clinically suspected COVID-19. The incidence rate of COVID-19 was 19.7/1000 person-years among users of SGLT2i and 24.7/1000 person-years among propensity score matched users of DPP4i. The adjusted hazard ratio was 0.92 (95% CI 0.66 to 1.29) and there was no evidence of residual confounding in the negative control analysis. We did not observe an increased risk of COVID-19 in primary care amongst those prescribed SGLT2i compared to DPP4i, suggesting that clinicians may safely use these agents in the everyday care of people with type 2 diabetes during the COVID-19 pandemic.
Sodium-Glucose-Co-Transporter-2 Inhibitors and Susceptibility to COVID-19: A Population-Based Retrospective Cohort Study
Diabetes Obes Metab 2020 Sep 29;[EPub Ahead of Print], C Sainsbury, J Wang, K Gokhale, D Acosta-Mena, S Dhalla, N Byne, JS Chandan, A Anand, J Cooper, K Okoth, A Subramanian, MN Bangash, T Taverner, W Hanif, S Ghosh, P Narendran, KK Cheng, T Marshall, G Gkoutos, K Toulis, N Thomas, A Tahrani, NJ Adderley, S Haroon, K Nirantharakumar